Study of Alirocumab (REGN727/SAR236553) added-on to Rosuvastatin Versus Other Lipid Modifying Treatments (LMT) (ODYSSEY OPTIONS II)

NCT01730053 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

305

Enrollment

INDUSTRY

Sponsor class

Conditions

Hypercholesterolemia

Interventions

DRUG: Alirocumab
DRUG: Rosuvastatin
DRUG: Ezetimibe
DRUG: Placebo

Sponsor

Regeneron Pharmaceuticals

Collaborators

[object Object]